Shin Seung Hwan, Park Sang Hyoung
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2022 Aug 25;80(2):51-59. doi: 10.4166/kjg.2022.096.
There has been a rise in the incidence of inflammatory bowel disease (IBD) in developing countries, including South Korea. Consequently, the use of immunosuppressive agents such as immunomodulators or biologics has also increased. Due to immunosuppression, patients on these agents are at increased risk of various opportunistic infections during treatment, which may sometimes lead to serious adverse outcomes. Viral hepatitis, especially hepatitis B, is one of the infectious conditions that can be reactivated during immunosuppressive therapy, and adequate strategies for monitoring and prophylaxis are needed to prevent it. South Korea is one of the countries with intermediate endemicity for hepatitis A and B. Thus, taking adequate precautions against viral hepatitis could prevent new infections or reactivation of these conditions in patients with IBD on immunosuppressive therapy. In this review article, we have summarized the latest evidence on viral hepatitis in patients with IBD that would be of assistance in clinical practice.
包括韩国在内的发展中国家,炎症性肠病(IBD)的发病率呈上升趋势。因此,免疫调节剂或生物制剂等免疫抑制剂的使用也有所增加。由于免疫抑制作用,接受这些药物治疗的患者在治疗期间发生各种机会性感染的风险增加,有时可能导致严重的不良后果。病毒性肝炎,尤其是乙型肝炎,是免疫抑制治疗期间可能被激活的感染性疾病之一,需要采取适当的监测和预防策略来预防。韩国是甲型和乙型肝炎中度流行的国家之一。因此,采取适当的预防措施预防病毒性肝炎,可以防止接受免疫抑制治疗的IBD患者出现新的感染或这些疾病的复发。在这篇综述文章中,我们总结了IBD患者病毒性肝炎的最新证据,这将有助于临床实践。